METRIX PARTNERS
For growing tech companies that need to build a first-in-class finance operation, Metrix Partners provides part-time CFO and financial advisory services, straight from the best peer companies and with a flexible cost arrangement.
WHY A CFO?
“A solid operating CFO is a blessing to an early stage CEO”. We concur with Firas Raouf from Openview Partners. When is the right time to hire a part-time CFO? How much does it cost?
MEET US
Meet our partners and find out what we can do for you.
CASES
From seed to unicorn.
Our client references.
NEWS FEED
AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement
AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure. AELIX Therapeutics will investigate the safety, immunogenicity, and efficacy of AELIX Therapeutics’ HTI vaccine and Gilead´s Toll-Like Receptor 7 agonist vesatolimod (GS-9620) in HIV-infected individuals. Read the full press release here
Our client Northern Biologics Enters the Clinic with its lead immuno-oncology antibody, MSC-1
Northern Biologics Inc., a developer of first-in-class immuno-oncology products, today announced that its lead immuno-oncology antibody, MSC-1, began clinical testing at Memorial Sloan Kettering Cancer Center with plans to soon expand to other world-leading sites in Canada and Europe. MSC-1 is a humanized antibody against a soluble cytokine called LIF (see “About LIF” below). LIF […]
Geoblink raises $6m and joins Metrix Partners' client list
Location intelligence SaaS company, Geoblink, has today announced that it has secured a $6m boost from Elaia Partners and existing investor Nauta Capital. The round includes grants from the Government of Madrid and Neotec CDTI, a public organisation for technology development in Spain. Founded in 2015, the European startup will use the funding to […]
What does it take to raise capital, in SaaS, in 2018?, by Christoph Janz
Note: this article was originally published in Medium by Christophe Janz, from Point Nine Capital What does it take to raise capital, in SaaS, in 2018? UPDATE: The 2018 napkin has been published. You can download (and upvote 😉 ) it here: https://www.producthunt.com/posts/saas-funding-napkin-2018 About two years ago I thought about the question of what it takes to raise capital, in […]
Our client ForceManager raises $12m in Series B Funding led by AXA Strategic Ventures
Post originally published in Nauta Capital’s blog on 06 Dec 2017 ForceManager raises $12m in Series B Funding led by AXA Strategic Ventures Barcelona, 6th December 2017 – ForceManager, the first AI conversational sales assistant app for field sales teams, announced today a Series B investment worth $12m led by AXA Strategic Ventures. Additional support will be […]
Hire a CFO by Jeff Jordan, from Andreessen Horowitz
This post was originally pubished in A16Z’s blog here. Many CEOs think the chief financial officer (CFO) is a utility position… and they’re dead wrong. It’s easy to see the CFO as a glorified “scorekeeper” reporting arrears on things like revenue, expenses, profit/losses, and cash flow/burn. But this work is actually a very small part of a […]
Our client Aelix commences enrolment in Phase I trial for HIV vaccine
Spanish biotechnology firm Aelix Therapeutics has commenced patient enrolment in a Phase I clinical trial (AELIX-002) of HTI vaccine to treat patients infected with HIV. Designed by the firm’s chief scientific officer Dr Christian Brander and colleagues, HTI vaccine immunogen combines specific HIV regions that are enriched with T-cell responses in individuals who can control […]
Northern Biologics merges with our client Mosaic Biomedicals as Versant, Celgene boost involvement
Canadian biotech Northern Biologics has signed a “transformative” merger deal with Spain’s Mosaic Biomedicals as the new player looks to become a global cancer company, eyeing 2017 in-human testing for its lead candidate. The early-stage, newly formed company gains more money, Big Biotech backing and a new exec. On the money side, investment firm Versant Ventures has […]